Neridronic acid for treating complex regional pain syndrome

Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as pain associated with complex regional pain syndrome.

What is claimed is: 
     
         1 . A method of treating complex regional pain syndrome, comprising parenterally administering neridronic acid, in an acid form or a salt form, to a human being in need thereof, wherein the neridronic acid is in a dosage form that is a solution. 
     
     
         2 . The method of  claim 1 , wherein the complex regional pain syndrome is accompanied by edema. 
     
     
         3 . The method of  claim 1 , wherein the complex regional pain syndrome is accompanied by severe pain. 
     
     
         4 . The method of  claim 1 , wherein the complex regional pain syndrome is accompanied by hyperalgesia. 
     
     
         5 . The method of  claim 1 , wherein the parenteral dose of the neridronic acid is about 5 mg to about 500 mg. 
     
     
         6 . The method of  claim 1 , wherein the parenteral dose of the neridronic acid is about 5 mg to about 200 mg. 
     
     
         7 . The method of  claim 1 , wherein the parenteral dose of the neridronic acid is about 10 mg to about 150 mg. 
     
     
         8 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome type I. 
     
     
         9 . The method of  claim 1 , wherein the human being is suffering from complex regional pain syndrome type II. 
     
     
         10 . The method of  claim 1 , wherein the neridronic acid is administered in combination with an oral zoledronic acid. 
     
     
         11 . The method of  claim 10 , wherein the zoledronic acid is administered orally. 
     
     
         12 . The method of  claim 10 , wherein the zoledronic acid is administered intravenously. 
     
     
         13 . The method of  claim 10 , wherein the zoledronic acid is the most potent bisphosphonate administered. 
     
     
         14 . The method of  claim 1 , wherein the CRPS was triggered by a traumatic event, and wherein the traumatic event was bone fracture. 
     
     
         15 . The method of  claim 1 , wherein the human being has a pain score of at least about 4 on the 0-10 numeric rating scale. 
     
     
         16 . The method of  claim 1 , wherein the neridronic acid is administered intravenously. 
     
     
         17 . The method of  claim 1 , wherein the neridronic acid is administered by controlled release or sustained release, wherein the neridronic acid is administered through a delivery device. 
     
     
         18 . The method of  claim 1 , wherein the neridronic acid is administered daily, weekly, monthly, every two months, every three months, once a year, or twice a year. 
     
     
         19 . The method of  claim 1 , wherein the treatment with the neridronic acid is effective in reducing pain. 
     
     
         20 . The method of  claim 1 , wherein the neridronic acid is administered in a dosage form that does not contain a bioavailability enhancer.